Arcellx and Kite Continue Anito-Cel Multiple Myeloma Program

Arcellx and Kite Continue Progress with Advances in Anito-Cel Multiple Myeloma Program

Overview

Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), have jointly announced significant operational advancements in their collaborative effort on the anitocabtagene autoleucel (anito-cel) program for multiple myeloma treatment. This innovative therapy, utilizing Arcellx's compact D-Domain binder, represents a breakthrough as the first BCMA CAR T therapy explored in multiple myeloma.

iMMagine-3 trial

• The focal point of these updates is the unveiling of the iMMagine-3 trial, a global Phase 3 randomized controlled clinical trial. 
• Expected to commence in the latter half of this year, this trial aims to compare the efficacy and safety of anito-cel against the current standard of care (SOC) for patients with relapsed and/or refractory multiple myeloma (rrMM). 
• These patients will have undergone one to three prior lines of therapy, including both an immunomodulatory drug (IMiD) and an anti-CD38 monoclonal antibody.

Manufacturing for Trial

• Manufacturing for this trial will take place at Kite's facility in Frederick, Maryland, following the successful technical transfer from a third-party manufacturing organization. 
• Additionally, the Investigational New Drug (IND) application for anito-cel has received clearance from the U.S. Food and Drug Administration.

Words from CEO: Arcellx

Rami Elghandour, Arcellx’s Chairman and CEO, emphasized the significance of the iMMagine-3 trial in addressing an unmet clinical need, particularly in patients who have been exposed to previous treatments. He highlighted the trial's ability to capture a substantial patient population and provide access to a unique segment of patients.

Kite on Unmet Needs

Kite, underscored the urgency of addressing the substantial unmet need in patients with relapsed and/or refractory multiple myeloma. She expressed confidence in leveraging Kite's manufacturing expertise to position anito-cel as a leading candidate in cell therapy.

The iMMagine-3 trial is designed to enroll approximately 450 adult patients across ~130 study sites globally. Patients randomized to the anito-cel arm will undergo a specific treatment regimen involving leukapheresis, optional bridging therapy, lymphodepleting chemotherapy, and infusion of anito-cel.

The Endpoints

The primary endpoint of the trial is progression-free survival (PFS), with key secondary endpoints including complete response rate, minimal residual disease negativity, overall survival, and safety parameters.

Collaborative Effort

• • The collaborative effort between Arcellx and Kite aims to co-develop and co-commercialize anito-cel for the treatment of relapsed or refractory multiple myeloma. 
• • Anito-cel's unique characteristics, including its novel D-Domain binder and regulatory designations, position it as a promising candidate in the treatment landscape.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!